Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees

By Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly January 2011, Vol. 16, No. 1
New Drug Reviews / Word Count: 2391 / Article # 06110101031

Executive Summary

The rate of first-cycle approvals of new molecular entities in 2010 eclipsed previous highs, suggesting that the regulatory innovations of the FDA Amendments Act are paying off in terms of review efficiency.

Purchase this Article

$85.00 Buy Now

For $85.00, purchase this 2391-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Few, But Fast And On Time: 2010 Saw Low NMEs, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 14

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article